【摘要】 目的探讨凝血纤溶系统的动态变化监测在冠状动脉粥样硬化性心脏病(CAHD)诊断和治疗中的应用价值。方法采用发色底物法对152例CAHD患者(CAHD组)及40例健康对照者(对照组)血浆抗凝血酶Ⅲ(ATⅢ)、蛋白C(PC)、纤溶酶原激活物抑制物-1(PAI-1)、凝血酶激活的纤溶抑制物活性(TAFI:A)水平进行检测。结果与对照组比较,CAHD组患者治疗前血浆ATⅢ、PC水平明显降低(P<0.05),PAI-1、TAFI:A水平明显升高(P<0.05);CAHD组患者治疗后,仅血浆PC水平与对照组比较差异有统计学意义(P<0.05)。结论血浆ATⅢ、PC、PAI-1、TAFI:A水平检测应用于CAHD的诊断和治疗具有一定的临床意义。更多还原

【Abstract】 Objective To explore the clinical value of the dynamic monitoring of blood coagulation and fibrinolysis system for the diagnosis and therapy of coronary atherosclerotic heart disease(CAHD).Methods 152 cases of patients with CAHD(CAHD group) and 40 healthy controls(control group) were enrolled and detected for the plasma levels of antithrombin Ⅲ(ATⅢ),protein C(PC),plasminogen activator inhibitor-1(PAI-1) and thrombin-activatable fibrinolysis inhibitor:activity(TAFI:A).Results Plasma levels of ATⅢ and PC in CAHD group,before being treated,were lower than control group(P<0.05),and those of PAI-1 and TAFI:A were higher than control group(P<0.05).After therapy,only plasma level of PC in CAHD group was lower than control group(P<0.05).Conclusion The detection of plasma level of ATⅢ,PC,PAI-1 and TAFI:A could have certain clinical value for the diagnosis of the diagnosis and therapy of CAHD.更多还原